- Home
- THAR vs BDRX Comparison
THAR vs BDRX Comparison
Compare THAR & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- BDRX
- Stock Information
- Founded
- THAR 2017
- BDRX 2000
- Country
- THAR United States
- BDRX United Kingdom
- Employees
- THAR N/A
- BDRX N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- BDRX Health Care
- Exchange
- THAR Nasdaq
- BDRX Nasdaq
- Market Cap
- THAR 3.3M
- BDRX 3.6M
- IPO Year
- THAR 2022
- BDRX N/A
- Fundamental
- Price
- THAR $1.51
- BDRX $1.15
- Analyst Decision
- THAR Strong Buy
- BDRX
- Analyst Count
- THAR 1
- BDRX 0
- Target Price
- THAR $17.00
- BDRX N/A
- AVG Volume (30 Days)
- THAR 26.3K
- BDRX 3.6M
- Earning Date
- THAR 05-12-2025
- BDRX 04-11-2025
- Dividend Yield
- THAR N/A
- BDRX N/A
- EPS Growth
- THAR N/A
- BDRX N/A
- EPS
- THAR N/A
- BDRX N/A
- Revenue
- THAR N/A
- BDRX N/A
- Revenue This Year
- THAR N/A
- BDRX N/A
- Revenue Next Year
- THAR N/A
- BDRX N/A
- P/E Ratio
- THAR N/A
- BDRX N/A
- Revenue Growth
- THAR N/A
- BDRX N/A
- 52 Week Low
- THAR $0.95
- BDRX $1.01
- 52 Week High
- THAR $6.39
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- THAR 54.61
- BDRX 39.66
- Support Level
- THAR $1.41
- BDRX $1.01
- Resistance Level
- THAR $1.64
- BDRX $1.26
- Average True Range (ATR)
- THAR 0.11
- BDRX 0.12
- MACD
- THAR 0.01
- BDRX 0.01
- Stochastic Oscillator
- THAR 63.86
- BDRX 15.22
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.